|Bid||82.87 x 200|
|Ask||82.90 x 500|
|Day's Range||82.51 - 83.22|
|52 Week Range||64.18 - 86.72|
|PE Ratio (TTM)||40.15|
|Dividend & Yield||2.08 (2.53%)|
|1y Target Est||N/A|
No analyst has recommended any form of "sell" for Pfizer stock.
Both in-house and M&A solutions will be risky and take time to bear fruit.
If you were running an R&D organization, would you use your precious resources to invest in diabetes R&D, or would you look at other important areas like cancer and rare diseases, where the need is great but the ultimate development costs are less?